Background: Non-invasive brain stimulation is being increasingly used to interrogate neurophysiology and modulate brain function. Despite the high scientific and therapeutic potential of non-invasive brain stimulation, experience in the developing brain has been limited.
INTRODUCTION
Transcranial magnetic stimulation (TMS) and transcranial direct-current stimulation (tDCS) are promising therapeutic and research tools. Over the past two decades, a large body of adult research exploring these non-invasive brain stimulation (NIBS) technologies has emerged [1, 2] . While the number of pediatric NIBS studies continues to grow [3] [4] [5] , the developing brain remains largely under-represented in the current literature. Of the >16000 human TMS/tDCS studies, only 675 (4%) have a pediatric focus. A review of tDCS studies to date found that <2% of nearly 7000 subjects were under 18 years of age [1] . This lack of evidence in a vulnerable population with unique neurobiology and disease states mandates the additional study of NIBS safety in children. This is especially pressing as scientists, clinicians, ethics boards, and concerned parents are seeking evidence when evaluating the potential risks of NIBS in children. The lack of evidence regarding NIBS safety and tolerability in youth is likely hampering progress across many brain and mental health disorders of the developing brain where the global burden of disease is large.
Safety and tolerability of TMS applications in adults has been well studied. When applied within established safety guidelines [6] , TMS paradigms are generally considered minimal risk [7] . Headache and neck pain are the most commonly reported adverse effects [8] [9] [10] but are typically mild and lasted for few minutes [11] . Although the use of high-frequency repetitive TMS (rTMS) has raised theoretical concerns of inducing seizures, this risk appears to be extremely low. A systematic review of 280 subjects with epilepsy who underwent rTMS reported seizures in only 1.4%, most of whom already had frequent seizures [9] . Other studies of at risk populations further suggest the risk of rTMSassociated seizure is <0.1% [8, 10, 12] . In one study of >250 healthy adult subjects, no seizures were reported.
Although similar studies are scarce in children, available evidence suggests similar safety. A review on the application of TMS across 322 children (3-17.8 years old) across 48 studies described potentially serious adverse events in 4 cases (1.2%). Two children had seizures possibly related to TMS while two others had syncope [13] . Headache (11.5%) was the most commonly reported side effect of rTMS in children [13] .
tDCS safety and tolerability data in adults is also well-established. A recent study by Bikson and colleagues [1] evaluated the safety of tDCS across >33,000 sessions in >7000 participants and found no serious adverse events. The same study also documented a paucity of experience in participants less than 18 years of age. Tingling, itching, and burning are the most commonly reported side effects in adults [14] . While systematic studies are lacking, the same appears to be true in children and serious adverse events have not been reported [15] .
The potential of NIBS is clearly evident in adults, with similar promise increasingly demonstrated in children and adolescents. While limited studies [13] have suggested the incidence of adverse events is <1%, there is a large disparity across populations, methods, and safety measures. Defining the safety and tolerability of NIBS across the different stages of developmental neurobiology and pediatric disease-states is essential. Families and research ethics boards remain concerned about the possible risks of NIBS in children, hindering progress. To address this gap in the literature, we report the safety and tolerability of TMS and tDCS in a large, prospective, and diverse sample of 382 children who received a total of more than 3.5 million stimulations within a structured pediatric NIBS program.
METHODS

Studies and Populations
All studies performed at the Alberta Children's Hospital Pediatric Non-invasive Brain Stimulation Laboratory (Calgary, Canada) since its inception in 2008 were reviewed for inclusion. Date of study ranged from January 1, 2009 to May 2018. Inclusion criteria for the current study were: (1) aged 0-18 years, (2) received one form of NIBS at least once, (3) completion of at least one Pediatric TMS Safety and Tolerability Measure [16] , and (4) informed consent/assent. All studies were approved by the University of Calgary Conjoint Health Research Ethics Board.
The details regarding each study, including age, condition and stimulation parameters, are summarized in Table 1 . A full description of the methods of each study is beyond the scope of this report. Additional details can be found in those studies already published [17] [18] [19] [20] [21] [22] [23] [24] [25] or are available online (e.g. clinicaltrials.gov).
Neurologically and developmentally normal (typically developed, controls)) participants were recruited from the community and the Healthy Infants and Children's Clinical Research Program (HICCUP, www.hiccupkids.ca). Inclusion and exclusion criteria were comparable across these studies including the absence of any neuropsychiatric/developmental diagnoses.
Equipment
Single-and paired-pulse TMS to the hand motor cortex was delivered using a figure-ofeight flat-iron, 70mm TMS coil (200 2 or BiStim2, Magstim, UK) and a double cone coil (Magstim, UK) to the leg motor area. Motor mapping and rTMS was performed using a figure-of-eight air-film coil (Rapid2, Magstim). Motor mapping was completed using a TMS Robot (Axilium, Strasbourg, France). Brainsight2 (Rogue, Montreal, Canada) was used for Neuronavigation. All tDCS trials used either a Neuroconn DC Stimulator (Neuroconn, Illmenau, Germany) or Soterix 1x1 Stimulator (Soterix Medical Inc., New York, USA) via two saline-soaked sponge electrodes (25 or 35cm 2 ). High Density (HD)-tDCS was delivered using a 4x1 HD Adapter (Soterix Medical Inc.), with four small circular electrodes oriented in a ring-like orientation around a central electrode (1.2cm diameter, Sintered ring HD-electrode, Soterix Medical Inc., New York), that was connected to a Soterix 1x1 Stimulator.
Neurophysiological Assessments
Single Pulse TMS Paradigms
All single pulse TMS studies employed a Magstim 200 2 stimulator and figure-of-eight flatiron coil. Single, suprathreshold (e.g. 120%RMT), pulses were typically given with 4-5 second intervals between stimuli. The motor 'hotspot' was the location in M1 that produced the largest and most consistent motor evoked potential (MEP). MEP measurements were normalized across individuals to resting and/or active motor thresholds. Resting motor threshold (RMT) was defined as the minimum TMS intensity that elicited reproducible MEP responses of at least 50µV in 5/10 consecutive stimuli [26] . Active motor threshold (AMT) was the minimum intensity to elicit responses of at least 200µV in 5/10 trials during active contraction at 10-20% of the maximum contraction strength (MVC) maintained via visual feedback. Stimulus Response Curves were input/output curves obtained in proportion to RMT/AMT by administering stimulations from 100% to 150% RMT (10% increments, 10 stimulations per intensity in a random order). Cortical silent period (cSP) was measured by delivering 15 pulses at 120% RMT during contraction of the contralateral hand at 20% of MVC. Ipsilateral silent period (iSP) was obtained by delivering 10 pulses at 120% RMT during concentration of the ipsilateral hand at 50% of MVC.
Paired Pulse TMS Paradigms
All paired-pulse TMS studies employed a pair of Magstim 200 2 stimulators connected to each other (Bistim2, Magstim) and two figure-of-eight flat-iron coils. A combined shortinterval intracortical inhibition (SICI) and intracortical facilitation (ICF) paradigm was comparable to methods described in adults [27] and our pediatric populations as reported in detail elsewhere [21] . Short-interval intracortical facilitation (SICF) [28, 29] and longinterval intracortical inhibition (LICI) protocols followed published evidence [30] . To assess interhemispheric inhibition (IHI), a test stimulus over one M1 was preceded by a conditioning stimulus of the opposite M1 including both short-(8-10ms) and long-(40-50ms) interstimulus intervals [31] [32] . Supra-threshold double pulse stimulation, both pulses 70 and 80% MSO and 10ms interstimulus interval (ISI), we delivered with double cone coil over leg M1 to facilitate recruitment of MEP in children < 4 years [33] .
Neuromodulation Paradigms
Four neuromodulatory paradigms were applied across studies based on adult evidence available at the time of study [34] . Repetitive TMS (rTMS) included low frequency at 1Hz and high frequency at 10Hz, both typically administered for 20-40 minutes. Paired afferent stimulation (PAS) were consistent with adult protocols [35, 36] including suprathreshold median nerve stimulation preceding M1 single pulse TMS at an ISI of 25ms.Traditional 1x1 tDCS also adhered to typical standards published in adults. Constant current was passed between two sponge electrodes using standard anodal and cathodal montages [37, 38] . HD-tDCS used an EEG cap system to surround a central active (anodal) electrode with four reference electrodes (cathodes) in a ring-like fashion to generate more focal currents over the desired cortical target.
Safety and Tolerability Measures
Pediatric NIBS Screening Form Prior to administering any form of neurostimulation, all participants completed noninvasive brain stimulation screening questionnaire [39] . The questionnaire aimed to identify participants with known contraindications (e.g. metal in the head, cardiac pacemaker, pregnancy) or those at any increased risk of complications (e.g. unstable epilepsy, history of syncope).
Pediatric NIBS Safety and Tolerability Assessment
In accordance with all studies being approved by the institutional research ethics board, a standardized process was in place for reporting of any potentially serious adverse events. Larger clinical trials may have also had formal data safety monitoring boards including medical safety officers with additional interim analyses and reporting procedures.
A modified pediatric TMS safety and tolerability measure [16] was administered at the end of all single session studies and at both first session and predefined time points in multisession studies. Possible adverse events (headache, presyncope, nausea, etc.) were screened and quantified (mild/moderate/severe). Any other potential side effects were recorded and quantified. Subjects also ranked their experience relative to 7 other common childhood experiences to assess relative tolerability. For example, the most favorable experience was rated as "1" (e.g. playing a game) and the least was rated as "8" (e.g. throwing up). The questions were read once to the child and they completed the ranking by themselves. In the case of very young children (<4 years old), no formal questionnaire was used. Parents were asked to report if their child was more irritable after the TMS session.
Statistical Analysis
To compare mean age differences between different modalities (TMS, rTMS and tDCs), a one-way ANOVA with post hoc Student's t-tests and Bonferroni-correction was performed. To compare differences in gender proportions, a Chi-Square Fisher Exact test was used. Logistic regression was used to test potential associations between age and tolerability rank and occurrence of side effects as well as RMT and occurrence of side effects. A Chi-Square Fisher Exact test was also used to compare percentage occurrence of side effects between different clinical populations. Analyses were performed using SPSS 25.0.
RESULTS
Populations
A total of 384 participants underwent at least one NIBS procedure. Mean age was comparable between the TMS (12.2±4.5 yrs) and tDCS (12.9±3.4 yrs) groups but was significantly higher in rTMS (13.6±3.4 yrs) groups (F=3.46, p=0.03). Gender proportions were comparable between all three modalities (χ 2 =2.24, p=0.69). Table 1 , 2 and 3 summarize the population demographics for neurophysiology TMS, rTMS and tDCS, respectively. Neurophysiological TMS included single-and paired-pulse TMS, and neuromodulatory TMS includes rTMS and tDCS. Over 3.5 million TMS stimulations were delivered in total. Neurophysiological studies (single and paired-pulse) included 383 participants (median age 13 years, range 0.8-18 years, 47% female). The most common conditions were children with typical development, perinatal stroke, and traumatic brain injury (TBI). A total of 542,340 single and paired TMS pulses were delivered across the neurophysiology protocols (Table 1 ).
Neuromodulation TMS for intervention studies included 119 participants (median age 14 years, range 6-21, 43% female) across 5 studies ( Table 2 ). The total number of rTMS pulses applied was 2,945,040. The most common conditions were children with typical development, major depressive disorder, and stroke.
Ninety-two participants had at least one tDCS session (median age 14 years, range 6-18, 38% female). Four studies applied tDCS with the most common populations being children with typical development and perinatal stroke. The motor cortex was the target of tDCS in all participants except for one participant where the target was the auditory cortex. The proportion of different tDCS approaches included anodal (22%), cathodal (34%), HD-tDCS (6%) and sham (37%). The median dose of electrical current applied was 1mA (range 1-2mA) ( Table 3 ). The duration for all tDCS was 20 minutes.
Serious Adverse Events and Dropouts
There were no serious adverse events. Despite 221(58%) participants having brain injuries and/or epilepsy, no seizures occurred in association with single, paired, or rTMS or with tDCS. Of 382 participants, only two drop outs occurred (<1%). Two adolescents (aged 15 and 17 years) with major depressive disorder (MDD), were undergoing high-frequency rTMS over the dominant DLPFC (of 28 in study). Both withdrew by the second session, reporting stimulation discomfort as the reason. Attempts at temporarily lowering stimulation intensity and optimizing coil orientation were not successful.
Adverse Events and Side Effects
The experienced sensations associated with TMS, rTMS and tDCS are summarized below and in Figure 1 . There was no association between age or resting motor threshold with any of the reported side effects (all r<0.2, p>0.4).
Headache
Across all neurophysiology studies, headache was reported in 13% of TMS sessions. As shown in Figure 1a , compared to typically developing, headache was more frequent in participants with perinatal stroke (χ 2 =13.8, p<0.001) and Tourette syndrome (χ 2 =18.3, p=0.02) but not TBI (χ 2 =1.3, p=0.52). All but 5% of headaches following TMS were ranked mild or moderate. TMS associated headache also appeared to decrease when procedures switched from landmarking on a swim-cap to neuronavigation though lack of record details prevented quantifying this effect.
Across all rTMS studies, headache was reported in <17% of TMS sessions. Headaches were more common in TBI subjects as compared to MDD (χ 2 =5.9, p=0.03). Headache occurrence was similar between typically developing and participants with Tourette syndrome (χ 2 =0.4, p=0.9), and participants with perinatal stroke (χ 2 =4.7, p=0.4).
Headache associated with active tDCS was reported in 25% of participants with perinatal stroke. In typically developing children, mild headache was reported in 9.5% (χ 2 =5.4, p=0.04). Presence of headache was not associated with type of tDCS (active or sham) both in typically developing (χ 2 =0.04, p=0.9) or stroke (χ 2 =0.05, p=0.9) participants.
Neck Pain
Overall, rTMS and TMS associated neck pain was reported in <30% of participants. Neck pain was reported in 33% of robotic TMS sessions. For TMS neurophysiology sessions, neck pain was less common in typically developing (8.7%) compared to stroke (17.8%, χ 2 =4.9, p=0.05), which was similar to Tourette (20.2%, χ 2 =2.7, p=0.1) and TBI (21.1%, χ 2 =3.6, p=0.1). Frequency of neck pain following rTMS was comparable across groups (all χ 2 =0.5, p=0.4). Severity of neck pain was mild and self-limiting and may have decreased with the adoption of neuronavigation. For tDCS, neck pain was uncommon with the highest reported incidence of 20% reported in the sham group of stroke participants.
Unpleasant Tingling
Most TMS neurophysiology sessions were not associated with unpleasant tinging (12%). Rates were comparable between typically developing, Tourette and TBI but more common in in stroke participants (31%, χ 2 =16.7, p<0.001, Figure 1a ). rTMS-associated tingling sensations were reported in <25% of participants overall and were comparable across groups. As shown in Figure 2c , following tDCS, 37% of participants experienced shortlasting tingling sensations under the tDCS electrodes. The sensation was always graded as mild or moderate and was comparable between the active and sham groups in both typically developing (χ 2 =3.4 p=0.6) and stroke (χ 2 =1.2, p=0.4) participants.
Presyncope
Light-headedness was uncommon, reported in 13% of all participants (Figure 1 ). Compared to typically developing controls, similar light-headedness was experienced by stroke (8%, χ 2 =0.9, p=0.4), TBI (9%, χ 2 =1.4, p=0.5), and Tourette syndrome (20%, χ 2 =6.3, p=0.1) participants following TMS neurophysiology sessions. Similarly, 30% of Tourette and 22% of TBI participants reported light-headedness following rTMS. Less than 10% of participants felt light-headed during tDCS sessions. There were no episodes of altered consciousness or termination of session due to these symptoms.
Itching and Burning
Scalp itching or burning was only assessed within tDCS studies. It was reported by 55% of participants, classified as mild and transient in all cases. As shown in Figure 1c , scalp itching was more common following active tDCS (70%) as compared to sham (36%, χ 2 =4.5, p=0.05) in typically developing children. However, the occurrence of itching did not differ between active treatment and sham in trials of perinatal stroke (n=25, χ 2 =3.6, p=0.1).
Burning sensations under the tDCS electrodes following active and sham stimulations were experienced by similar proportions of 20% and 14% respectively in typically developing children. Similarly, 10% of stroke participants reported burning sensations, the proportion of which did not differ between active and sham tDCS. Subjects were not able to guess their assigned treatment group across multiple studies [17, 19, 22] .
Nausea
Mild nausea was the least reported sensation following TMS, rTMS, and tDCS, occurring in 2%, 10%, and 5% respectively. There was no significant difference across groups (all χ 2 <2.0, p>0.5).
Study specific adverse event screening: Motor Skills
Individual studies included pre-specified functional safety outcomes. Multiple clinical trials of contralesional rTMS [40] and tDCS in hemiparetic children with perinatal stroke demonstrated no decrease in function of either hand including specific tests of unaffected hand function. Likewise, motor cortex tDCS did not decrease function of either hand in typically developing children.
Tolerability Rankings
Initial questionnaires (recorded in the first session) were completed by all 367 participants with 339 of these subjects having repeated assessments over time (see below). TMS, rTMS, and tDCS tolerability results are summarized in Figure 2 . The width of the bars show the range of scores from all children where 1 is the most preferred activity of the 8 presented and 8 is the least preferred. The stars represent the median value. For the first TMS session, mean tolerability rank score was 4.3±1.7. Similarly, for the first rTMS treatment, mean tolerability rank score was 4.3±1.5. For first tDCS session (n=92), mean tolerability rank score was 4.4±1.5. No association was observed between participant age and tolerability ranking for TMS (r=0.22), rTMS (r=0.32), or tDCS (r=0.16, all p>0.31). For all 3 modalities, participants ranked the experience between attending a birthday party (3.6±1.6) and a long card ride (4.8±1.7). Mean rankings of TMS did not differ between clinical populations (F=2.71, p=0.06). Rankings for high frequency rTMS was worse in MDD group compared to TBI group (5.3 vs 4.7, F=5.83, p<0.001) but not compared to other groups. tDCS ranking did not differ between typically developing and stroke groups or between active and sham treatments (F=0.825, p=0.49).
Change in Side Effects
Tolerability changed over time (Figure 3 ). Following repeated sessions of single and paired-pulse TMS, the percent occurrence of all side-effects (headaches, neck pain, tingling, nausea and lightheadedness) remained below 5% in typically developing children (Figure 3a) . In stroke subjects, headache, neck pain and tingling occurrence decreased by 16% (p=0.04), 16% (p=0.04), and 20% (p=0.04), respectively (Figure 3b ). For rTMS, weekly tolerability assessments in MDD participants saw headache decrease by 40% (p=0.04) by the second week and was <5% (p=0.02) by the third week (Figure 3c ). All other side effects also decreased by at least 5% by the third week. Headache decreased by 25% (p=0.03) by the fourth week in participants with TBI ( Figure 3d ). In participants with perinatal stroke, all rTMS side effects were initially reported in <10% and decreased to <5% at the end of the second week (Figure 3e ). Headache and neck pain remained stable over 2 weeks in participants with TICS ( Figure 3f ).
In typically developing children, occurrence of itching following tDCS decreased by 48 % (p=0.05) during day 3 (Figure 3g) . A decrease in all side effects (p<0.05), except for neck pain, were seen in participants with perinatal stroke undergoing tDCS (Figure 3h ).
DISCUSSION
In this largest, prospective, single-center pediatric cohort to date, we provide substantial new evidence supporting the safety, feasibility, and favourable tolerability of NIBS in children. Both neurophysiological (single-and paired-pulse TMS) and neuromodulatory (rTMS, tDCS) modalities were well-tolerated with no serious adverse events across millions of stimulations and hundreds of children with a variety of neurological conditions. Combined with existing evidence, our study supports the conclusion that established NIBS modalities can be considered minimal risk in school-aged children. Safety conclusions are made based on lack of severe adverse effects, such as seizure, hearing damage or pain.
Thousands of adults have received rTMS across a broad range of neurological and mental health conditions [41] . Guidelines first published in 1998 [6] and now updated [41] provide clear parameters for established practices. Particular attention to safety in well designed, large trials of common populations has supported this evidence base. For example, in a large, sham-controlled rTMS trial for adults with treatment resistant MDD [42] , there was no difference in adverse events by treatment arm (active rTMS and sham). No seizures occurred and a single occurrence of syncope was deemed unlikely to be related to the study [42] . Large controlled, blinded trials of rTMS for adult pain including thorough side effect screening during and after sessions also reported no adverse effects [43] . Despite this huge experience in adults, only isolated case incidents of possible TMS-or rTMSassociated seizures have been reported [44] . To date, pediatric NIBS studies have generally lacked such power to systematically explore safety issues in specific populations.
Issues of TMS safety in children have been previously considered across a variety of small series and pooled analyses. Single-pulse and paired-pulse TMS has been used to assess brain maturation, neurophysiology, and motor development safely in the developing brain [45, 46] . Across 75 TMS studies involving >2000 children and adolescents, no serious adverse events were reported [16, 47] . Accordingly, experts have suggested that single-and paired-pulse TMS studies confer only minimal risk to children [33] . With rTMS however, there is less experience. Heightened concerns for rTMS exposure include seizure risk, hearing damage, pain, and neurocognitive effects. Safety and ethical issues regarding the use of rTMS in adolescents was reviewed by Croarkin et al. [48] .
There are limited studies reporting about safety of theta burst stimulation in children. A study that characterized the effect of theta burst stimulation in typically developing children and those with Tourette's Syndrome, there was no serious adverse events [49] . Similar study compared the safety of theta bust stimulation with single and paired pulse stimulation in 165 children and found no seizure or severe adverse events [50] .
The application of tDCS to pediatric populations has been increasing rapidly. However, this population continues to be under-represented in comparison to adults [1] , and there remains a pressing need to investigate the mechanisms, behavioural effects, and safety of tDCS in the developing brain. Unique anatomy and the developmental changes that take place throughout childhood suggest that tDCS effects will vary and differ from adults. For example, the developing brain is thought to have a shifted balance of excitation-inhibition, resting closer to the seizure-threshold [51] . Our studies have not identified any seizure-like activity, and epileptogenic monitoring by others supports this finding [52] .
Previous investigations in adults suggesting no decline in psychomotor function, verbal fluency, emotional behaviour or other neuropsychological [53] effects are important but require replication in children with age-adjusted outcome measures. Work by our group suggests that application of five concurrent days of conventional tDCS and HD-tDCS, in typically-developing children, does not cause any changes in neurocognitive function, measured using the CNS Vitals assessment [22] . Longitudinal tDCS studies in children have been few and additional studies on sequential dosing are required.
A recent safety analysis found no serious adverse effects reported in nearly 500 children receiving tDCS over 2800 sessions [13] . While these findings support safety of the application of tDCS in children, additional considerations are required. Evidence from computational current modeling suggests that local electric field strength may be two-fold greater in children compared to adults [54] [55] . A large study from our team suggests that peak electric fields in cortical grey matter may be up to seven-fold higher in children compared to adults [56] . Current strengths of 2mA (current density of 0.80mA/cm 2 ) appear to be equally tolerable as both 1mA (current density of 0.40mA/cm 2 ) and sham tDCS [15] . Likewise, tolerability of 1mA HD-tDCS is comparable to that of 1mA conventional tDCS [22] . Another pediatric-specific review of the safety of NIBS technologies also suggested that tDCS is safe in children with underlying neurological or psychiatric conditions [13] . While tingling, itching, redness and scalp discomfort were reported in pediatric populations, the incidence of these findings appeared to be lower than in adults [14] . In contrast, studies that employed rigorous tDCS-sensation reporting as a prespecified outcome found incidence rates in children and adolescents similar to those reported in adults [15] . While the tolerability and feasibility of standard tDCS practices in children appears to be confirmed, vigilance toward additional complex and study-specific safety outcomes remains essential.
A limitation of our tolerability and safety assessments is the lack of long term follow up data, as well as, the lack of standardized and comprehensive tools to assess the complete status of the participant before and after brain stimulation. Using the methods described above, other important factors that may have influenced tolerability of TMS and tDCS, such as stress level, fatigue, sleep, hearing and vision conditions were not considered. As a result, we propose an improved pediatric NIBS tolerability form (Appendix A). The improved NIBS tolerability questionnaire considers mental status before the start of stimulation, including the amount of sleep the participant had the night before, headache patterns, drug or alcohol use. It also includes behavioural observations during the session. In the same way that the original TMS tolerability form of Garvey et al [16] has served as a valuable tool in over the first 25 years of pediatric brain stimulation, we hope this model might facilitate further progress in the future.
In conclusion, we demonstrate safety and tolerability of the most common NIBS modalities and paradigms in pediatric populations, spanning a broad age range and variety of clinical conditions. Both TMS and tDCS appear to pose minimal risk to school-aged children, however, best practices with a focus on patient safety remain paramount. Routine use of prospective, study-specific safety and tolerability evaluations should be used in all pediatric NIBS studies. Due to the lack of pediatric-specific guidelines, we suggest that established adult guidelines be combined with emerging evidence and careful consideration of relevant pediatric issues to best advance neurostimulation research in children.
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